Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes

• Published in: Canadian journal of ophthalmology Vol. 45; no. 4; pp. 386 - 392
• Main Authors: Xu, Weiqi, MD, PhD, Wang, Hong, MD, Wang, Fenghua, MD, PhD, Jiang, Yuan, MD, Zhang, Xian, MD, Wang, Wenqiu, MD, Qian, Jin, MD, Xu, Xun, MD, PhD, Sun, Xiaodong, MD, PhD
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.08.2010
• Subjects: Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - toxicity; Animals; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - toxicity; Antibodies, Monoclonal, Humanized; Apoptosis - drug effects; Bevacizumab; drug toxicity; Electroretinography - drug effects; Evoked Potentials, Visual - drug effects; In Situ Nick-End Labeling; Injections; Internal Medicine; Intraocular Pressure - drug effects; intravitreal injection; Microscopy, Acoustic; Ophthalmology; rabbit eyes; Rabbits; retina; Retina - drug effects; Retina - ultrastructure; Retreatment; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vitreous Body; bevacizumab; intravitreal injection; rabbit eyes; drug toxicity; retina
• ISSN: 0008-4182; 1715-3360
• DOI: 10.3129/i10-024

Abstract Objective: To evaluate the potential toxicity of repeated intravitreal injections of bevacizumab in rabbit eyes. Design: Randomized, placebo-controlled experimental animal study. Participants: Fourteen chinchilla rabbits; 12 assigned to the experimental group and 2 assigned to the normal control group. Methods: Three sequential, biweekly, intravitreal injections of bevacizumab in doses of 2.5 mg/0.1 mL or 5.0 mg/0.2 mL were performed on each rabbit. Evaluations included intraocular pressure (IOP), aqueous flare, B-scan ultrasound, fundus photography, ultrasound biomicroscopy, electroretinography (ERG), and visually evoked potentials (VEPs) performed at baseline and during the follow-up period. The eyes were enucleated at 1 week and 4 weeks after the last intravitreal injection, and underwent light and electron microscopic evaluations, as well as testing for apoptotic activity. Results: After intravitreal injections, no changes were found by regular clinical observation and IOP tests. There was no significant difference in the anterior chamber inflammatory activity evaluated by the laserflare meter. No evidence of retinal toxicity was seen after intravitreal bevacizumab at doses of 2.5 and 5.0 mg by either ERG or flash VEPs. Electron microscopy did show the presence of inflammatory cells and some ultrastructural changes in the photo-receptor cells in the 5.0 mg experimental group 1 week after the third injection. Mild to moderate apoptosis of photoreceptors was detected in the 5.0 mg group at the same time. Conclusions: The biweekly, multiple intravitreal injections of bevacizumab did not result in evidence of toxicity in regular clinical and functional observations at both 2.5 mg and 5.0 mg doses. The 5.0 mg dose may induce transient inflammation, ultrastructural abnormalities, and apoptosis.